Guggenheim Capital LLC Decreases Stake in Illumina, Inc. (NASDAQ:ILMN)

Guggenheim Capital LLC lessened its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 65.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,107 shares of the life sciences company’s stock after selling 43,278 shares during the period. Guggenheim Capital LLC’s holdings in Illumina were worth $3,088,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc grew its position in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares in the last quarter. Golden State Wealth Management LLC acquired a new stake in shares of Illumina in the 4th quarter worth $32,000. Assetmark Inc. raised its holdings in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after acquiring an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Illumina during the 4th quarter valued at about $45,000. Finally, Lee Danner & Bass Inc. purchased a new stake in shares of Illumina in the fourth quarter valued at about $48,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Performance

Shares of Illumina stock opened at $71.21 on Friday. The business has a 50-day simple moving average of $84.61 and a 200-day simple moving average of $120.27. The company has a market cap of $11.27 billion, a PE ratio of -9.27, a P/E/G ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Citigroup decreased their target price on shares of Illumina from $90.00 to $85.00 and set a “neutral” rating on the stock in a report on Monday, April 7th. TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Robert W. Baird reduced their target price on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. Hsbc Global Res cut Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. Finally, HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective on the stock. in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Illumina has an average rating of “Moderate Buy” and an average target price of $138.70.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.